PROJECT

Projects

Environmental & Social Review Summary

Project Number

48236

Company Name

Shanghai Desano Bio-pharmaceutical Co., Ltd.

Date ESRS Disclosed

Jul 22, 2024

Country

China

Region

East Asia and the Pacific

Last Updated Date

Oct 25, 2025

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jun 4, 2024
Signed : Jun 8, 2024
Invested : Dec 16, 2024

Sector

other

Industry

other

Department

Regional Industry - MAS Asia & Pac

Project Description

Headquartered in Shanghai, China, Shanghai Desano Bio-Pharmaceutical Co., Ltd. (“Desano” or the “Company”) is a leading manufacturer of Active Pharmaceutical Ingredients (“API”) and finished dosage forms (“FDF”) for the treatment of HIV-AIDS. The company sells its API products utilized by its domestic and overseas corporate drug manufacturing clients to produce generic antiretroviral (ARV) drugs.  Also the company sells FDF products in China and exports them globally.

IFC is considering a Loan of US$100 million to support the Company’s expansion program in China and India. The Company’s expansion program includes: (1) construction and operation of Phase 2 of ARV API production facility in Zhangshu City, Jiangxi province, China (location coordinates: 28.022611, 115.624583), where production of the Phase 1 started in mid-2023 (Phase 2 is currently at the planning stage, with construction expected to commence in the first quarter of 2025); and (2) expansion of its ARV API and FDF manufacturing facility in Harohalli, KIADB Industrial Area, Phase III, Ramanagar District, Karnataka, India (location coordinates: 12.774250815282588, 77.63640036591903) (“Desano Harohalli”). In India the greenfield Project facility is currently undergoing construction with 80% of civil works completed.

Overview of IFC's Scope of Review

IFC’s appraisal of this proposed investment consisted of a review of available environmental, health, safety (EHS), and social documents and the Company’s responses to a series of E&S questionnaires. IFC’s appraisal includes: (1) a review of: the feasibility study for Zhangshu Phase 2 ARV API facility; an environmental impact assessment (EIA) report for Phase 1 of the Desano Zhangshu and the Desano Harohalli ARV API manufacturing facilities; Zhangshu Phase 1 facility energy efficiency report; Zhangshu Phase 1 monthly waste discharge monitoring results, indoor noise and air quality monitoring reports (including parameters: acetone; HCl; Ethyl acetate; sodium carbonate; n-hexane; toluene; Isopropyl alcohol; etc.), and anonymous workers health checkup results; the Company’s corporate EHS policies and procedures and Human Resources (HR) management documents; EHS training records; and EHS monitoring and audit reports for Zhangshu Phase 1 facility; (2) IFC site visits in December 2023 to Desano Zhangshu and Desano Harohalli India production facilities. During site visits, interviews were conducted with the Company’s senior management including the heads and team members of EHS, occupational health and safety (OHS), HR, facility and equipment maintenance departments, and with operational staff at various functional areas of visited facilities.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan